Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q2 2026

Autonomix Medical Q2 2026 Results: Net Loss of $3.13M, Loss Narrows

Autonomix Medical, Inc. reported a net loss of $5.85 million for the six months ended September 30, 2026, an improvement from the $10.79 million loss in the prior year period. The company strengthened its balance sheet through warrant exercises, ending the period with $7.69 million in cash and cash equivalents while continuing to develop its proprietary catheter-based sensing and RF ablation technologies.

Q2 2026 at a glance · $ million
MetricQ2 2026Q2 2025
Revenue0.00.0
Profit before tax-3.1-7.5
Net income-3.1-7.5
EPS (diluted, $ a share)$-2.51$-29.02

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: AMIX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Autonomix Medical, Inc.: key numbers

Share price
$1.08Close, Nov 17
Market cap
$2.21M
Shares outstanding
2.05MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Autonomix Medical, Inc.

All →
5:01 PM ET 8-K
Shareholder Meeting

Autonomix Medical Shareholder Meeting

Autonomix Medical held its 2026 Annual Meeting of Stockholders on October 29, 2026, where shareholders elected six directors and ratified Forvis Mazars, LLP as the independent auditor. Stockholders also approved an amendment to the 2023 Stock Plan to increase authorized shares by 750,000 and granted the Board authority to effect a reverse stock split at a ratio between 1-for-2 and 1-for-25.

8:36 AM ET 8-K
Leadership Change

Autonomix Medical Leadership Change

Autonomix Medical has appointed Sandra Kalter, the former Chief Regulatory Counsel and Vice President of Medtronic, to its Board of Directors, increasing the board size from five to six members. Ms. Kalter brings over 40 years of MedTech experience, including regulatory strategy and M&A due diligence for major medical device platforms. She will participate in the company's standard compensation program for non-employee directors.

Counterparty
Sandra Kalter

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.